Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Kröger, Nicolaus  [Clear All Filters]
2019
Radujkovic, A., Dietrich, S., Blok, H.-J., Nagler, A., Ayuk, F., Finke, J., Tischer, J., Mayer, J., Koc, Y., Sorà, F., et al. (2019). Allogeneic stem cell transplantation for blast crisis chronic myeloid leukemia in the era of tyrosine kinase inhibitors - A retrospective study by the EBMT Chronic Malignancies Working Party.Biol Blood Marrow Transplant.
Daghia, G., Zabelina, T., Zeck, G., von Pein, U.-M., Christopeit, M., Wolschke, C., Ayuk, F., and Kröger, N. (2019). Allogeneic stem cell transplantation for myelofibrosis patients aged ≥ 65 years.Eur J Haematol.
Palmer, J., Kosiorek, H.E., Wolschke, C., Fauble, V.D.S., Butterfield, R., Geyer, H., Scherber, R.M., Dueck, A.C., Gathany, A., Mesa, R.A., et al. (2019). Assessment of Quality of Life Following Allogeneic Stem Cell Transplant for Myelofibrosis.Biol Blood Marrow Transplant.
Zeiser, R., Beelen, D.W., Bethge, W., Bornhäuser, M., Bug, G., Burchert, A., Christopeit, M., Duyster, J., Finke, J., Gerbitz, A., et al. (2019). Biology-driven approaches to prevent and treat relapse of myeloid neoplasia after allogeneic hematopoietic stem cell transplantation.Biol Blood Marrow Transplant.
Kröger, N. (2019). Induction, bridging or straight ahead the ongoing dilemma of allografting in advanced MDS.Biol Blood Marrow Transplant.
Ringdén, O., Boumendil, A., Labopin, M., Canaani, J., Beelen, D., Ehninger, G., Niederwieser, D., Finke, J., Stelljes, M., Gerbitz, A., et al. (2019). OUTCOME OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS OVER 69 YEARS OF AGE WITH ACUTE MYELOID LEUKEMIA: ON BEHALF OF THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT.Biol Blood Marrow Transplant.
Gagelmann, N., Eikema, D.-J., Koster, L., Caillot, D., Pioltelli, P., Lleonart, J.Bargay, Reményi, P., Blaise, D., Schaap, N., Trneny, M., et al. (2019). Tandem autologous stem cell transplantation improves outcome in newly diagnosed multiple myeloma with extramedullary disease and high-risk cytogenetics: a study from the Chronic Malignancies Working Party of EBMT.Biol Blood Marrow Transplant.
2018
Triviai, I., Zeschke, S., Rentel, J., Spanakis, M., Scherer, T., Gabdoulline, R., Panagiota, V., Thol, F., Heuser, M., Stocking, C., et al. (2018). ASXL1/EZH2 mutations promote clonal expansion of neoplastic HSC and impair erythropoiesis in PMF.Leukemia.
Raj, K., Eikema, D.-J., McLornan, D.P., Olavarria, E., Blok, H.-J., Bregante, S., Ciceri, F., Passweg, J., Ljungman, P., Schaap, N., et al. (2018). Family mismatched allogeneic stem cell transplantation for Myelofibrosis: Report from the Chronic Malignancies Working Party of EBMT.Biol Blood Marrow Transplant.
Robin, M., Porcher, R., Ruggeri, A., Blaise, D., Wolschke, C., Koster, L., Angelucci, E., Stölzel, F., Potter, V., Yakoub-Agha, I., et al. (2018). HLA mismatched donors in patients with myelodysplastic syndrome: an EBMT registry analysis.Biol Blood Marrow Transplant.
Canaani, J., Beohou, E., Labopin, M., Ghavamzadeh, A., Beelen, D., Hamladji, R.-M., Niederwieser, D., Volin, L., Markiewicz, M., Arnold, R., et al. (2018). Trends in patient outcome over the past two decades following allogeneic stem cell transplantation for acute myeloid leukemia. An ALWP/EBMT analysis.J Intern Med.
2016
Kröger, N., Solano, C., Wolschke, C., Bandini, G., Patriarca, F., Pini, M., Nagler, A., Selleri, C., Risitano, A., Messina, G., et al. (2016). Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease.N Engl J Med374, 43-53.
Kuba, K., Esser, P., Scherwath, A., Schirmer, L., Schulz-Kindermann, F., Dinkel, A., Balck, F., Koch, U., Kröger, N., Götze, H., et al. (2016). Cancer-and-treatment-specific distress and its impact on post-traumatic stress in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT).Psychooncology.
Robin, M., Porcher, R., Wolschke, C., de Fontbrune, F.Sicre, Alchalby, H., Christopeit, M., Cassinat, B., Zabelina, T., de Latour, R.Peffault, Ayuk, F., et al. (2016). Outcome after transplantation according to reduced intensity conditioning regimen in patients transplanted for myelofibrosis.Biol Blood Marrow Transplant.
Schieferdecker, A., Shoshani, O., Westner, B., Zipori, D., Fehse, B., Kröger, N., and Ayuk, F. (2016). Potent in vitro and in vivo effects of polyclonal anti-human-myeloma globulins.Oncotarget.
Gratwohl, A., Iacobelli, S., Bootsman, N., van Biezen, A., Baldomero, H., Arcese, W., Arnold, R., Bron, D., Cordonnier, C., Ernst, P., et al. (2016). Splenic irradiation before hematopoietic stem cell transplantation for chronic myeloid leukemia: long-term follow-up of a prospective randomized study.Ann Hematol.
Bruno, B., Auner, H.W., Gahrton, G., Garderet, L., Festuccia, M., Ladetto, M., Lemoli, R.M., Massaia, M., Morris, C., Palumbo, A., et al. (2016). Stem cell transplantation in multiple myeloma and other plasma cell disorders (report from an EBMT preceptorship meeting).Leuk Lymphoma1-13.
Ruggeri, A., Battipaglia, G., Labopin, M., Ehninger, G., Beelen, D., Tischer, J., Ganser, A., Schwerdtfeger, R., Glass, B., Finke, J., et al. (2016). Unrelated donor versus matched sibling donor in adults with acute myeloid leukemia in first relapse: an ALWP-EBMT study.J Hematol Oncol9, 89.
2015
Derlin, T., Clauditz, T.Sebastian, and Kröger, N. (2015). 18F-FDG PET/CT for Detection of Leukemic Transformation in Myelofibrosis.Clin Nucl Med.
Triviai, I., Stübig, T., Niebuhr, B., Hussein, K., Tsiftsoglou, A., Fehse, B., Stocking, C., and Kröger, N. (2015). CD133 marks a stem cell population that drives human Primary Myelofibrosis.Haematologica.
Stahl, T., Böhme, M., Kröger, N., and Fehse, B. (2015). Digital PCR to assess haematopoietic chimaerism after allogeneic stem cell transplantation.Exp Hematol.
Xavier, E., Cornillon, J., Ruggeri, A., Chevallier, P., Cornelissen, J.J., Andersen, N.S., Maillard, N., Nguyen, S., Blaise, D., Deconinck, E., et al. (2015). Outcomes of Cord Blood Transplantation Using Reduced Intensity Conditioning for Chronic Lymphocytic Leukemia: a Study on Behalf of Eurocord and Cord Blood Committee of Celular Therapy and Immunobiology Working Party(CTIWP), Chronic Malignancies Working Pa.Biol Blood Marrow Transplant.
van der Torren, C.R., van Hensbergen, Y., Luther, S., Aghai, Z., Rychnavská, Z.Stachová, Slot, M., Scherjon, S., Kröger, N., Ganser, A., Weissinger, E.M., et al. (2015). Possible Role of Minor H Antigens in the Persistence of Donor Chimerism after Stem Cell Transplantation; Relevance for Sustained Leukemia Remission.Plos One10, e0119595.
2014
Stübig, T., Badbaran, A., Luetkens, T., Hildebrandt, Y., Atanackovic, D., Binder, T.M.C., Fehse, B., and Kröger, N. (2014). 5-azacytidine promotes an inhibitory T-cell phenotype and impairs immune mediated antileukemic activity.Mediators Inflamm2014, 418292.
Chalandon, Y., Passweg, J.R., Guglielmi, C., Iacobelli, S., Apperley, J., Schaap, N.P.M., Finke, J., Robin, M., Fedele, R., Bron, D., et al. (2014). Early administration of donor lymphocyte infusions upon molecular relapse after allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia: a study by the Chronic Malignancies Working Party of the EBMT.Haematologica.

Pages